Boehringer
Boehringer hopes to be perfect fit for Tessellate’s lead cancer programme
Malignant Neoplasms, Boehringer, ALT-positive, Ingelheim, cellular targeting
Boehringer boards B-cell depletion bandwagon, paying Cue $12M to line up autoimmune attack
Cues, CUE-501, B-Lymphocytes, Boehringer, Depletion, paying, T-Lymphocyte
Boehringer Ingelheim’s Nerandomilast Achieves Second Phase III Success in Pulmonary Fibrosis Treatment
Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive pulmonary fibrosis, idiopathic pulmonary fibrosis, lung function, forced vital capacity
Boehringer Ingelheim’s Nerandomilast Succeeds in Second Phase III Lung Fibrosis Trial, Paving Way for FDA Approval
Nerandomilast, Boehringer Ingelheim, Phase III trial, FIBRONEER-ILD, progressive fibrosing interstitial lung diseases (PF-ILDs), lung function improvement, FDA approval, phosphodiesterase 4B (PDE4B) inhibitor
Synaffix Expands ADC Licensing Partnerships with Boehringer Ingelheim and Mitsubishi Tanabe
Synaffix, Boehringer Ingelheim, Mitsubishi Tanabe, ADC technology, oncology, cancer treatment, licensing agreement
WCLC24 Highlights: ArriVent’s Drug Aims to Address Tagrisso’s Limitations; Boehringer and Bayer Share Data on HER2-Mutated Lung Cancer
WCLC24, ArriVent, Tagrisso, Boehringer, Bayer, HER2-mutated lung cancer, Lung cancer treatment, EGFR-mutated lung cancer
Medicare Drug Price Negotiation Program Upheld in Court, Defeating Boehringer Ingelheim’s Challenge
Medicare, drug pricing, negotiation program, Boehringer Ingelheim, legal challenge, pharmaceutical industry, healthcare policy
Pharmaceutical Giants Secure Victory in Initial Zantac Lawsuit
Zantac, GSK, Boehringer Ingelheim, lawsuit, victory, heartburn medication, ranitidine, NDMA